Generic drug makerLabelled by claude-haiku-5.5 from the firm's FDA names. It is not an FDA field. in IndiaLabelled by claude-haiku-5.5 from the firm's FDA names. It is not an FDA field.. FDA records under 3 spellings of its name, each linked to the record.
As of Nov 14, 2026, FDA's public records list Intas Pharmaceuticals and its 2 subsidiaries with 174 drug applications, 107 drug recalls, 12 complete response letters and 3 warning letters. The most recent is a drug recall dated Jun 10, 2026: IMULDOSA, (ustekinumab-srlf) Injection, 130 mg/26 mL (5mg/mL), Rx only, Single dose vial….
Drug approvals, 510(k) clearances, recalls and letters, 2017 to 2026 to date, Intas Pharmaceuticals and its 2 subsidiaries
A hatched bar is a year that is not over, so its count covers only part of the year.
Spellings are joined only when they reduce to the same name, or a reviewed source names the same company. Sharing an FDA establishment number (FEI) is not enough: contract sites make products for many firms. Facts marked AI were labelled by a language model from the firm's FDA names; everything else comes from FDA or Wikidata. How this page is built
